Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial
Pourdowlat et al.,
Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized..,
Phytotherapy Research, doi:10.1002/ptr.7319
RCT 202 patients in Iran, 102 treated with colchicine, showing lower hospitalization and improved clinical outcomes with treatment.
risk of hospitalization, 72.8% lower, RR 0.27, p = 0.004, treatment 5 of 102 (4.9%), control 18 of 100 (18.0%), NNT 7.6.
|
relative improvement in dyspnea, 37.5% better, RR 0.62, p = 0.03, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.
|
relative improvement in Ct score, 22.4% better, RR 0.78, p = 0.048, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Pourdowlat et al., 2 Feb 2022, Randomized Controlled Trial, Iran, peer-reviewed, 18 authors.
Abstract: Received: 10 May 2021
Revised: 29 September 2021
Accepted: 12 October 2021
DOI: 10.1002/ptr.7319
RESEARCH ARTICLE
Efficacy and safety of colchicine treatment in patients with
COVID-19: A prospective, multicenter, randomized clinical trial
Guitti Pourdowlat1
|
Fatemeh Saghafi2
|
Abolfazl Mozafari3 |
Adeleh Sahebnasagh4 | Atefeh Abedini1 | Mohsen Nabi Meybodi5 |
Ali Salehi Nezamabadi6 | Seyed Ruhollah Mousavinasab7 | Arda Kiani8
9
10
|
| Mehdi Gholmzadeh Baeis
| Esmaeil Eidani12 |
Hanieh Raji | Nadia Soltani
Abdolrahim Sadeghi Yakhdani13 | Fatemeh Movaseghi3 | Solomon Habtemariam14 |
Zohreh Akhoundi Meybodi15 |
11
Mohsen Gholinataj Jelodar16
1
Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical
Sciences, Tehran, Iran
2
Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3
Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran
4
Clinical Research Center, Department of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
5
Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
6
Department of Cardiology, Tehranpars Hospital, Tehran, Iran
7
Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
8
Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences,
Tehran, Iran
9
Department of Internal Medicine, Air pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
10
Pharmaceutical Sciences Research Center, School of Pharmacy, Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
11
Department of Radiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
12
NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
13
Department of Radiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
14
Pharmacognosy Research Laboratories and Herbal Analysis Services UK, University of Greenwich, Kent, UK
15
Infectious Disease Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
16
Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Correspondence
Mohsen Gholinataj Jelodar, Department of
Internal Medicine, Faculty of Medicine, Shahid
Sadoughi University of Medical Sciences, Yazd,
Iran.
Email: dr.natajm@gmail.com
Abstract
Colchicine has shown clinical benefits in the management of COVID-19 via its antiinflammatory effect. However, the exact role of colchicine in COVID-19 patients is
unknown. The current clinical trial was performed on 202 patients with moderate to
severe COVID-19. Patients were randomly assigned in a 1:1 ratio to receive up to a
3-day course of 0.5 mg colchicine followed by a 12-day course of 1 mg colchicine in
combination with standard care or a 15-day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or
List of Abbreviations:..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit